Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVE-2 is a specific low-molecular-weight fraction (approximately 12,500 to 15,500 Da) of the divinyl ether-maleic anhydride (DIVEMA) copolymer, a synthetic polyanionic polymer also known as pyran copolymer. It functions as a pleiotropic biological response modifier and immunomodulator. MVE-2 primarily acts by activating macrophages, inducing the production of interferon, and stimulating natural killer (NK) cell activity, thereby enhancing the host's antitumor and antiviral defenses. In experimental oncology, it has been utilized as an adjuvant in tumor vaccines to induce specific syngeneic antitumor immunity, particularly in murine models of B-16 melanoma. While it showed potent immunostimulatory effects in preclinical research, its clinical development was historically limited by the systemic toxicities associated with higher molecular weight fractions of polyanionic polymers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MVE-2.